Jardiance (Empagliflozin)

Empagliflozin works by selectively blocking the sodium‑glucose co‑transporter‑2 (SGLT2) in the kidneys. This inhibition prevents reabsorption of filtered glucose, causing excess glucose to be expelled in the urine, which lowers plasma glucose levels and contributes to modest reductions in blood pressure and body weight.

The appropriate dose of empagliflozin is determined by the prescribing healthcare professional based on the individual’s medical condition, renal function, and concomitant therapies. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety data for empagliflozin during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Jardiance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Empagliflozin shares the core mechanism of SGLT2 inhibition with other agents in its class, such as canagliflozin and dapagliflozin. Clinical studies have highlighted its strong cardiovascular benefit, particularly in reducing heart‑failure‑related outcomes, while safety profiles are broadly comparable. Choice among agents often depends on individual patient characteristics, renal function, and prescriber preference.

Jardiance tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Jardiance is taken orally, usually once daily in the morning, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically advised by the prescriber.

Serious adverse events associated with empagliflozin include euglycemic diabetic ketoacidosis, acute kidney injury, severe hypersensitivity reactions such as anaphylaxis, and rare but life‑threatening infections like Fournier’s gangrene. Patients should seek immediate medical attention if they experience symptoms such as persistent nausea, vomiting, abdominal pain, rapid breathing, severe dehydration, or unusual skin changes.

Jardiance is contraindicated in individuals with a known hypersensitivity to empagliflozin or any component of the formulation. It should also be avoided in patients with severe renal impairment (eGFR below the threshold set by local guidelines), end‑stage renal disease, or those on dialysis. Clinicians must assess each patient’s medical history before initiating therapy.